The development of a therapeutic strategy for post-acute sequelae of COVID-19 should be based on an efficient classification of pathogenesis

The treatment of post-acute sequelae to COVID-19 (PASC) remains challenging. Defining PASC solely based on symptoms and disease duration in clinical trials can mask the potential for recovery in specific patient subgroups. A good design for future research requires a clear classification of various PASC according to different pathogenesis under the general diagnosis. Here, we discuss four key types of pathogenesis that should be recognized to determine the enrollment of PASC patients.